Evaluating Cadonilimab for Cervical Cancer Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the efficacy, safety, and cost-effectiveness of Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, in patients with persistent, recurrent, or metastatic cervical cancer. It involves collecting clinicopathological data and medical imaging results to assess treatment outcomes based on RECIST criteria. Additionally, the study monitors adverse events and laboratory test results to evaluate safety, while also conducting a survival benefit analysis related to medical expenses. The research aims to explore the relationship between genetic mutations and the drug's efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* •Persistent, recurrent or metastatic cervical cancer;

  * The pathological types are squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma;
  * No combination with other multiple primary cancers;
  * MRI before treatment Or CT examination, according to RECIST evaluation standards, there is at least one measurable lesion;
  * ECOG score 0-1 points.
  * Subjects gave informed consent, voluntarily cooperated with clinical follow-up, and signed informed consent forms.

Exclusion Criteria:

* Patients with other histopathological types of cervical cancer, such as small cell carcinoma, clear cell carcinoma, sarcoma, etc.;

  * Previous treatment with immune checkpoint inhibitors;
  * There are drug contraindications, such as liver function Insufficiency, renal insufficiency, etc.
  * The patient withdraws the informed consent;
  * The researcher determines that the patient is not suitable to participate in this clinical study.

Where it's running

• No. 420 Fuma Road, Jin'an District, Fuzhou City, Fujian Province
  Fuzhou, Fujian, China Recruiting

Study contacts

• Study coordinator: Yang Sun, Master
• Email: doctorsunyang@sina.com
• Phone: 15959028989

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination treatment for recurrent cervical cancer

  This study is testing a new combination of treatments for people with recurrent cervical cancer to see if it helps them feel better and live longer.

  Recruiting Phase 2 Zhongnan Hospital · Wuhan, Hubei · NCT05817214

• Cervical screening and care options for women living with HIV who test positive for high-risk HPV

  This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.

  Recruiting University of California, San Diego · Nairobi · NCT07925307

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• Hydrogel spacer to protect the rectum during cervical cancer radiotherapy

  This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07904182

• How cinema sessions during chemotherapy might help cervical cancer patients

  We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07902180

• One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy

  This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07895212

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.